Introduction: The RANK ligand inhibitor denosumab has been used to treat cases of unresectable giant cell tumors of bone (GCTB) or preoperatively to facilitate intralesional curettage. However, there are no clear guidelines for use of denosumab prior to en bloc resection. Case Presentation: In this study, a 26-year-old patient presented with atraumatic lateral knee pain. X-rays demonstrated a destructive lesion within the proximal fibula, and biopsy confirmed the diagnosis of GCTB. Management and Outcomes: The patient received 3 months of neoadjuvant denosumab with complete resolution of his pain and cortical rim formation surrounding the tumor. The tumor was removed en bloc with negative margins. At 6-month follow-up, the patient had returned to his functional baseline with no evidence of tumor recurrence. Conclusion: Neoadjuvant denosumab can mitigate symptoms related to GCTB and promotes cortical bone formation, facilitating en bloc resection and permitting acceptable functional outcomes in select cases.
Introduction: The RANK ligand inhibitor denosumab has been used to treat cases of unresectable giant cell tumors of bone (GCTB) or preoperatively to facilitate intralesional curettage. However, there are no clear guidelines for use of denosumab prior to en bloc resection. Case Presentation: In this study, a 26-year-old patient presented with atraumatic lateral knee pain. X-rays demonstrated a destructive lesion within the proximal fibula, and biopsy confirmed the diagnosis of GCTB. Management and Outcomes: The patient received 3 months of neoadjuvant denosumab with complete resolution of his pain and cortical rim formation surrounding the tumor. The tumor was removed en bloc with negative margins. At 6-month follow-up, the patient had returned to his functional baseline with no evidence of tumor recurrence. Conclusion: Neoadjuvant denosumab can mitigate symptoms related to GCTB and promotes cortical bone formation, facilitating en bloc resection and permitting acceptable functional outcomes in select cases.
Entities:
Keywords:
Giant cell tumor; denosumab; en bloc; neoadjuvant; resection
Authors: Matthew P Abdel; Panayiotis J Papagelopoulos; Mark E Morrey; Doris E Wenger; Peter S Rose; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2010-11 Impact factor: 4.176
Authors: A E Wijsbek; B L Vazquez-Garcia; R J Grimer; S R Carter; A A Abudu; R M Tillman; L Jeys Journal: Bone Joint J Date: 2014-01 Impact factor: 5.082
Authors: Sant Chawla; Robert Henshaw; Leanne Seeger; Edwin Choy; Jean-Yves Blay; Stefano Ferrari; Judith Kroep; Robert Grimer; Peter Reichardt; Piotr Rutkowski; Scott Schuetze; Keith Skubitz; Arthur Staddon; David Thomas; Yi Qian; Ira Jacobs Journal: Lancet Oncol Date: 2013-07-16 Impact factor: 41.316
Authors: Isabella W Y Mak; Nathan Evaniew; Snezana Popovic; Richard Tozer; Michelle Ghert Journal: J Bone Joint Surg Am Date: 2014-08-06 Impact factor: 5.284
Authors: Piotr Rutkowski; Stefano Ferrari; Robert J Grimer; Paul D Stalley; Sander P D Dijkstra; Andrzej Pienkowski; Gualter Vaz; Jay S Wunder; Leanne L Seeger; Amy Feng; Zachary J Roberts; Bruce A Bach Journal: Ann Surg Oncol Date: 2015-06-02 Impact factor: 5.344
Authors: Daniel A Müller; Giovanni Beltrami; Guido Scoccianti; Domenico A Campanacci; Alessandro Franchi; Rodolfo Capanna Journal: World J Surg Oncol Date: 2016-11-04 Impact factor: 2.754
Authors: Czar Louie Gaston; Robert J Grimer; Michael Parry; Silvia Stacchiotti; Angelo Paolo Dei Tos; Hans Gelderblom; Stefano Ferrari; Giacomo G Baldi; Robin L Jones; Sant Chawla; Paolo Casali; Axel LeCesne; Jean-Yves Blay; Sander P D Dijkstra; David M Thomas; Piotr Rutkowski Journal: Clin Sarcoma Res Date: 2016-09-14